View Single Post
Old 11-29-2013, 03:55 PM   #2
donocco
Senior Member
 
Join Date: Oct 2013
Posts: 438
Re: Australia study: Denosumab in Young Patients With Primary Breast Cancer

Interesting. Denosumab inhibits the Receptor Activator of Nuclear Factor Kappa Beta or that Rankl abbreviation. Nuclear Factor Kappa Beta or NFK-B is very active in the growth, motility and metastasis of cancer cells.

NSAIDS like Aspirin and Motrin also inhibit NFK-B. New information states they actually stimulate it but it becomes inactive. It gets confusing but the end action seems to be either direct or indirect inhibition. This is why they use Aspirin to decrease the incidence of colon cancer. Im not sure if this is an FDA approved use for Aspirin.

I remember way back in the 1990s an article in the American Journal of Epidemiology where, in a retrospective study it showed that women who took Motrin at least 4 days out of the week had a breast cancer rate 50% less than those who did not. Of course this was only one study.



Paul
donocco is offline   Reply With Quote